Table 3.
Prevalence of Resistance Mutations in RT and PR Genesa
| Drug class | Mutations |
Subtype B (n = 64) |
CRF_02AG (n = 7) |
B/G (n = 1) |
Total (n = 72) |
|---|---|---|---|---|---|
| Protease inhibitors | L10I | 2 (3.1) | 2 (2.8) | ||
| L10V | 1 (1.6) | 1 (1.4) | |||
| K20R | 4 (6.3) | 4 (5.6) | |||
| K20I | 7 (100.0) | 7 (9.7) | |||
| M36I | 24 (37.5) | 5 (71.4) | 1 (100.0) | 30 (41.7) | |
| M36P | 2 (3.1) | 1 (14.3) | 3 (4.2) | ||
| M36L | 1 (1.6) | 1 (1.4) | |||
| L63P | 32 (50.0) | 2 (28.6) | 1 (100.0) | 35 (48.6) | |
| A71V | 3 (4.7) | 3 (4.2) | |||
| A71T | 3 (4.7) | 3 (4.2) | |||
| V77I | 1 (1.6) | 1 (1.4) | |||
| Reverse transcriptase inhibitors | K103N | 1 (1.6) | 1 (14.3) | 2 (2.8) | |
| Y188C | 1 (1.6) | 1 (1.4) | |||
| No resistance mutations | 10 (15.6) | 0 | 0 | 10 (13.9) | |
| Mutations to one or more classes | 54 (84.4) | 7 (100.0) | 1 (100.0) | 62 (86.1) | |
| Mutations to > 1 class | 1 (1.6) | 1 (14.3) | 0 | 2 (2.8) | |
| Mutations to > 2 classes | 0 | 0 | 0 | 0 |
a
Numbers in parentheses indicate percentages.